Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study
The present study provides a unique look at real world cardiac event rates for a large group of multiple myeloma (MM) patients treated with selected anti-MM treatments. The cardiac event risk for any cardiac event, including hypertensive or arterial events, cardiac dysrhythmias, congestive heart failure, ischemic heart disease, cardiomyopathy, and conduction disorders, was greater in MM patients with ≥ 3 previous drugs (n = 1723) compared with patients without MM (n = 8615).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Kristin D. Kistler, Jill Kalman, Gagan Sahni, Brian Murphy, Winifred Werther, Kanya Rajangam, Ajai Chari Tags: Original Study Source Type: research
More News: Cardiology | Cardiomyopathy | Congestive Heart Failure | Heart | Heart Disease | Heart Failure | Hematology | Leukemia | Lymphoma | Myeloma | Study